1.15
Fate Therapeutics Inc stock is traded at $1.15, with a volume of 1.84M.
It is up +3.60% in the last 24 hours and down -7.26% over the past month.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$1.11
Open:
$1.11
24h Volume:
1.84M
Relative Volume:
1.10
Market Cap:
$132.63M
Revenue:
$13.45M
Net Income/Loss:
$-178.23M
P/E Ratio:
-0.697
EPS:
-1.65
Net Cash Flow:
$-132.53M
1W Performance:
+5.50%
1M Performance:
-7.26%
6M Performance:
-19.01%
1Y Performance:
-69.50%
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics Inc
Sector
Industry
Phone
858.875.1803
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
FATE
Fate Therapeutics Inc
|
1.15 | 138.40M | 13.45M | -178.23M | -132.53M | -1.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-18-24 | Upgrade | BofA Securities | Underperform → Neutral |
Jun-17-24 | Upgrade | Piper Sandler | Neutral → Overweight |
Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
Jan-24-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
Jan-06-23 | Downgrade | Cowen | Outperform → Market Perform |
Jan-06-23 | Downgrade | Piper Sandler | Overweight → Neutral |
Jan-06-23 | Downgrade | Stifel | Buy → Hold |
Jan-06-23 | Downgrade | Truist | Buy → Hold |
Jan-06-23 | Downgrade | Wedbush | Outperform → Neutral |
Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
Dec-15-22 | Initiated | Goldman | Sell |
Nov-04-22 | Resumed | Cantor Fitzgerald | Overweight |
Oct-10-22 | Initiated | Canaccord Genuity | Buy |
Aug-18-22 | Resumed | Wells Fargo | Overweight |
Jul-28-22 | Initiated | Needham | Hold |
Jul-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jun-03-22 | Initiated | Robert W. Baird | Neutral |
Feb-11-22 | Resumed | BMO Capital Markets | Market Perform |
Dec-15-21 | Upgrade | Wedbush | Neutral → Outperform |
Dec-07-21 | Initiated | Cowen | Outperform |
Nov-09-21 | Upgrade | Citigroup | Neutral → Buy |
Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
Jun-07-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
May-07-21 | Upgrade | Wedbush | Neutral → Outperform |
Apr-26-21 | Resumed | Jefferies | Buy |
Feb-26-21 | Initiated | BofA Securities | Buy |
Feb-26-21 | Downgrade | Wedbush | Outperform → Neutral |
Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
Jan-27-21 | Resumed | H.C. Wainwright | Neutral |
May-13-20 | Initiated | H.C. Wainwright | Buy |
Mar-04-20 | Initiated | Barclays | Overweight |
Jan-09-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Dec-30-19 | Reiterated | Mizuho | Buy |
Dec-09-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
Nov-12-19 | Initiated | SunTrust | Buy |
Nov-06-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
Oct-01-19 | Initiated | Stifel | Buy |
Aug-09-19 | Initiated | BTIG Research | Buy |
Jul-22-19 | Initiated | Cantor Fitzgerald | Overweight |
Jul-12-19 | Initiated | Oppenheimer | Outperform |
Jun-13-19 | Initiated | Mizuho | Buy |
Jun-07-19 | Initiated | ROTH Capital | Neutral |
May-31-19 | Initiated | Guggenheim | Buy |
May-24-19 | Resumed | Citigroup | Buy |
Mar-28-19 | Initiated | SVB Leerink | Outperform |
Jan-03-19 | Downgrade | Stephens | Overweight → Equal-Weight |
Nov-05-18 | Initiated | Jefferies | Buy |
Aug-01-18 | Initiated | Citigroup | Buy |
Mar-06-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
View All
Fate Therapeutics Inc Stock (FATE) Latest News
Layoff Tracker: Opthea Slashes 80% of Workforce, 50% of Board - BioSpace
Fate Therapeutics Inc. Rebound Backed by Sentiment ShiftJuly 2025 Snapshot & Precise Swing Trade Alerts - newsyoung.net
Fate Therapeutics Announces Corporate Restructuring Plan - MSN
Fate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors - MSN
Live Scanner Shows Breakout on Fate Therapeutics Inc.Gold Moves & Technical Entry and Exit Alerts - metal.it
RSI Suggests Rebound May Be Near in Fate Therapeutics Inc.Quarterly Profit Summary & Weekly Hot Stock Watchlists - kangso.co.kr
BofA Securities Adjusts Fate Therapeutics Price Target to $2 From $2.20, Maintains Neutral Rating - MarketScreener
Fate Therapeutics' Price Target Cut to $2.50 by Wells Fargo - AInvest
Barclays Maintains Buy Rating on Fate Therapeutics with $2.00 Price Target - AInvest
Is Now a Good Time to Reenter Fate Therapeutics Inc.Risk Management & Low Drawdown Momentum Trade Ideas - newsyoung.net
Fate Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Fate Therapeutics’ SWOT analysis: biotech stock navigates clinical progress amid financial challenges - Investing.com
Fate Therapeutics Reports Q2 2025 Financial Results - TipRanks
Fate Therapeutics Inc. Bounces Off Moving Average SupportCPI Data & Long-Term Growth Stock Strategies - beatles.ru
Fate Therapeutics shares rise 4.42% after-hours after reporting better-than-expected Q2 earnings. - AInvest
Fate Therapeutics Soars 28% on Earnings Optimism and Strategic Shifts - AInvest
Fate Therapeutics shares surge 26.07% intraday after Q2 earnings beat expectations and cash runway extended to 2027. - AInvest
FATE's 24.4% Surge: Clinical Breakthroughs and Strategic Restructuring Ignite Biotech Volatility - AInvest
A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $2 to $6 - 富途牛牛
Fate Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Wells Fargo lowers Fate Therapeutics stock price target to $2.50 on cost cuts - Investing.com Canada
Fate Therapeutics 2025 Q2 Earnings Narrowed Losses but Revenue Falls Sharply - AInvest
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Bullish Divergence Spotted in Fate Therapeutics Inc. MomentumAccurate Buy Point for Momentum Stocks Detected - 선데이타임즈
Cautious Hold Rating on Fate Therapeutics Amid Promising CAR-iT Developments and Early Stage Trials - TipRanks
Fate Therapeutics earnings beat by $0.05, revenue topped estimates - Investing.com Canada
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Fate Therapeutics' Q2 2025 Earnings: A Strategic Catalyst for Long-Term Shareholder Value - AInvest
Fate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Can machine learning forecast Fate Therapeutics Inc. recoveryBuy Opportunity Forecast for Fast Traders - Newser
What makes Fate Therapeutics Inc. stock price move sharplyHigh Conviction Stock Long-Term Summary - Newser
Why Fate Therapeutics Inc. stock attracts strong analyst attentionFree Real Time Trade Opportunity Alerts - Newser
Analyzing net buyer seller activity in Fate Therapeutics Inc.Free Entry and Exit Strategy Optimizer Tool - Newser
Fate Therapeutics Inc. stock trend forecastFree Risk Controlled Picks With Real Returns - Newser
Fate Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Trapped Investors in Fate Therapeutics Inc. Await Breakout SignalWatchlist for Smart Swing Trading Updated - metal.it
Fate Therapeutics shares fall 4.52% intraday due to unspecified reasons. - AInvest
Full technical analysis of Fate Therapeutics Inc. stockSwing Trade Picks with High Potential - Newser
Fate Therapeutics shares fall 4.17% intraday after granting non-qualified stock options to a new employee. - AInvest
Fate Therapeutics CEO Makes a Notable Stock Sale! - TipRanks
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics' Strategic Talent Acquisition and Equity Incentive Program: A Catalyst for Biotech Innovation and Shareholder Value - AInvest
Fate Therapeutics reports new employee inducement awards - MarketScreener
Fate Therapeutics CEO Valamehr sells $15,396 in stock By Investing.com - Investing.com Nigeria
Fate Therapeutics CEO Valamehr sells $15,396 in stock - Investing.com
Cwm LLC Buys 37,290 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics (NASDAQ:FATE) Upgraded at Wall Street Zen - Defense World
Fate Therapeutics Inc. Nearing Breakout Level After BounceAccurate Technical Trend Reversal Picks Detected - metal.it
What catalysts could drive Fate Therapeutics Inc. stock higher in 2025Capitalize on trading strategies that deliver - Jammu Links News
What is the dividend policy of Fate Therapeutics Inc. stockFree Stock Market Return Analysis - Jammu Links News
How strong is Fate Therapeutics Inc. company’s balance sheetFree Capital Efficiency Planning - Jammu Links News
Fate Therapeutics Inc Stock (FATE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fate Therapeutics Inc Stock (FATE) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Valamehr Bahram | President and CEO |
Aug 04 '25 |
Sale |
1.06 |
14,466 |
15,396 |
334,898 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):